Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Azelaprag · BGE-105

Small molecule · Agonist of apelin receptor (APJ) (APLNR) · developed by BioAge Labs

Phase 2 Most advanced trial (none active)
BIOA Developer
2 Registered trials

What is Azelaprag?

Azelaprag (BGE-105) is an oral agonist of the apelin receptor (APJ), a G protein-coupled receptor. It is studied in healthy volunteers and in obesity.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BGE-105
Drug type
Small molecule
Targets
apelin receptor (APJ) (APLNR)
Mechanism
Agonist of apelin receptor (APJ) (APLNR)
Therapy area
Metabolic
Developer
BioAge Labs, Inc. (BIOA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
4B8REJ8ZGY

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06515418 Phase 2 Obesity Terminated BIOA
NCT06141889 Phase 1 Healthy Volunteer Study Completed BIOA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Volunteer StudyObesity

Other drugs acting on APLNR

More from BioAge Labs

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BIOA page.

Follow BIOA, the company behind Azelaprag

See BIOA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BIOA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.